Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of three bevacizumab-containing first-line regimens in metastatic colorectal cancer
2005-000285-39Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Roche. Primary endpoints: Time to disease progression and Best response rate. Started Nov 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2005-000285-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000285-39.